Refine
Has Fulltext
- yes (24)
Is part of the Bibliography
- yes (24)
Document Type
- Journal article (24)
Language
- English (24)
Keywords
- adrenocortical carcinoma (5)
- CYP2W1 (2)
- Cushing’s syndrome (2)
- FGFR (2)
- SOAT1 (2)
- adrenal tumours (2)
- immunotherapy (2)
- machine learning (2)
- metabolomics (2)
- 18F-FDG (1)
- 2-deoxy-2-(18F)fluoro-D-glucose (1)
- ACTH (1)
- CRH stimulation test (1)
- CTNNB1 (1)
- CXCR4 (1)
- CXCR7 (1)
- CYP2B6 (1)
- Cushing syndrome (1)
- Cushing's disease (1)
- Cushing’s disease (1)
- EMT (1)
- FGF-pathway (1)
- NCI-H295R (1)
- NR3C1 (1)
- PD-L1 (1)
- PET (1)
- Positronen-Emissions-Tomografie (1)
- RNA Expression (1)
- RNAScope (1)
- SNP (1)
- TKI (1)
- USP8 (1)
- [18F]FDG-PET-CT (1)
- abdominal lymph node metastases (1)
- adjuvant platinum-based chemotherapy (1)
- adrenal (1)
- adrenal glands (1)
- adrenal imaging (1)
- adrenocortical carcinoma (ACC) (1)
- adrenocortical tissues (1)
- adrenocortical tumors (1)
- amphiphilic block copolymer (1)
- autonomous cortisol secretion (1)
- biomarker (1)
- biomarkers (1)
- cancer treatment (1)
- carcinomas (1)
- cardiovascular events (1)
- cardiovascular risk factors (1)
- catecholamines (1)
- chemokine receptor (1)
- cholesterol metabolism (1)
- combination (1)
- confounders (1)
- dexamethasone suppression test (1)
- diagnosis (1)
- drug therapy (1)
- ectopic (1)
- endogenous hypercortisolism (1)
- epithelial markers (1)
- feature selection (1)
- glucocorticoid excess (1)
- high dose dexamethasone suppression test (1)
- hormones (1)
- hypercortisolism (1)
- hypertension (1)
- immune check inhibitor (1)
- immune checkpoint inhibitor (ICI) (1)
- immune response (1)
- immunity (1)
- immunohistochemistry (1)
- immunohistochemistry techniques (1)
- lymphocytes (1)
- mass spectronomy (1)
- medullary thyroid cancer (1)
- medullary thyroid carcinoma (1)
- mesenchymal markers (1)
- mitotane (1)
- molecular diagnostics (1)
- morbidity (1)
- mortality (1)
- multi-tyrosine kinase inhibitor (1)
- multicenter (1)
- mutation triggers (1)
- normal adrenal glands (1)
- papillary thyroid carcinoma (PTC) (1)
- paraganglioma (1)
- parathyroid carcinoma (1)
- patient survival (1)
- pembrolizumab (1)
- personalized medicine (1)
- pheochromocytoma (1)
- pheochromocytoma/paraganglioma (1)
- phosphorylation (1)
- plasma NMR (1)
- poly(2-oxazoline) (1)
- positron emission tomography (1)
- preanalytical conditions (1)
- predictive marker (1)
- primary aldosteronism (1)
- prognosis (1)
- prognostic factors (1)
- prostate cancer (1)
- radical resection (1)
- radioiodine (1)
- radiotherapy (RT) (1)
- rearranged during transfection (1)
- recurrence-free survival (1)
- repeated surgery (1)
- selpercatinib (1)
- solubility enhancement (1)
- surgical oncology (1)
- survival (1)
- t-lymphocytes (1)
- target therapies (1)
- targeted metabolomics (1)
- thyroid carcinoma (TC) (1)
- treatment outcome (1)
- tumor microenvironment (1)
- tumor-infiltrating (1)
- tyrosine kinase inhibitor (1)
- tyrosine kinase inhibitor (TKI) (1)
- unsupervised clustering (1)
- vandetanib (1)
- variant (1)
Institute
- Medizinische Klinik und Poliklinik I (24) (remove)
Sonstige beteiligte Institutionen
Adrenocortical carcinoma (ACC) is a rare endocrine malignancy and treatment of advanced disease is challenging. Clinical trials with multi-tyrosine kinase inhibitors in the past have yielded disappointing results. Here, we investigated fibroblast growth factor (FGF) receptors and their pathways in adrenocortical tumors as potential treatment targets. We performed real-time RT-PCR of 93 FGF pathway related genes in a cohort of 39 fresh frozen benign and malignant adrenocortical, 9 non-adrenal tissues and 4 cell lines. The expression of FGF receptors was validated in 166 formalin-fixed paraffin embedded (FFPE) tissues using RNA in situ hybridization (RNAscope) and correlated with clinical data. In malignant compared to benign adrenal tumors, we found significant differences in the expression of 16/94 FGF receptor pathway related genes. Genes involved in tissue differentiation and metastatic spread through epithelial to mesechymal transition were most strongly altered. The therapeutically targetable FGF receptors 1 and 4 were upregulated 4.6- and 6-fold, respectively, in malignant compared to benign adrenocortical tumors, which was confirmed by RNAscope in FFPE samples. High expression of FGFR1 and 4 was significantly associated with worse patient prognosis in univariate analysis. After multivariate adjustment for the known prognostic factors Ki-67 and ENSAT tumor stage, FGFR1 remained significantly associated with recurrence-free survival (HR=6.10, 95%CI: 1.78 – 20.86, p=0.004) and FGFR4 with overall survival (HR=3.23, 95%CI: 1.52 – 6.88, p=0.002). Collectively, our study supports a role of FGF pathways in malignant adrenocortical tumors. Quantification of FGF receptors may enable a stratification of ACC for the use of FGFR inhibitors in future clinical trials.
Mutations in the PRKACA gene are the most frequent cause of cortisol-producing adrenocortical adenomas leading to Cushing’s syndrome. PRKACA encodes for the catalytic subunit α of protein kinase A (PKA). We already showed that PRKACA mutations lead to impairment of regulatory (R) subunit binding. Furthermore, PRKACA mutations are associated with reduced RIIβ protein levels; however, the mechanisms leading to reduced RIIβ levels are presently unknown. Here, we investigate the effects of the most frequent PRKACA mutation, L206R, on regulatory subunit stability. We find that Ser\(^{114}\) phosphorylation of RIIβ is required for its degradation, mediated by caspase 16. Last, we show that the resulting reduction in RIIβ protein levels leads to increased cortisol secretion in adrenocortical cells. These findings reveal the molecular mechanisms and pathophysiological relevance of the R subunit degradation caused by PRKACA mutations, adding another dimension to the deregulation of PKA signaling caused by PRKACA mutations in adrenal Cushing’s syndrome.
Purpose: The metabolically most active lesion in 2-deoxy-2-(\(^{18}\)F)fluoro-D-glucose (\(^{18}\)F-FDG) PET/CT can predict progression-free survival (PFS) in patients with medullary thyroid carcinoma (MTC) starting treatment with the tyrosine kinase inhibitor (TKI) vandetanib. However, this metric failed in overall survival (OS) prediction. In the present proof of concept study, we aimed to explore the prognostic value of intratumoral textural features (TF) as well as volumetric parameters (total lesion glycolysis, TLG) derived by pre-therapeutic \(^{18}\)F-FDG PET.
Methods: Eighteen patients with progressive MTC underwent baseline \(^{18}\)F-FDG PET/CT prior to and 3 months after vandetanib initiation. By manual segmentation of the tumor burden at baseline and follow-up PET, intratumoral TF and TLG were computed. The ability of TLG, imaging-based TF, and clinical parameters (including age, tumor marker doubling times, prior therapies and RET (rearranged during transfection) mutational status) for prediction of both PFS and OS were evaluated.
Results: The TF Complexity and the volumetric parameter TLG obtained at baseline prior to TKI initiation successfully differentiated between low- and high-risk patients. Complexity allocated 10/18 patients to the high-risk group with an OS of 3.3y (vs. low-risk group, OS=5.3y, 8/18, AUC=0.78, P=0.03). Baseline TLG designated 11/18 patients to the high-risk group (OS=3.5y vs. low-risk group, OS=5y, 7/18, AUC=0.83, P=0.005). The Hazard Ratio for cancer-related death was 6.1 for Complexity (TLG, 9.5). Among investigated clinical parameters, the age at initiation of TKI treatment reached significance for PFS prediction (P=0.02, OS, n.s.).
Conclusions: The TF Complexity and the volumetric parameter TLG are both independent parameters for OS prediction.